Biotech entity
fda-approval is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Dobbs v. Jackson Women's Health Organization, the most common co-covered peer. We currently track 1 Biotech story that mention Dilation and Curettage (D&C), all published on July 21, 2026.
Last mentioned: Jul 21, 2026
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
fda-approval is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Dobbs v. Jackson Women's Health Organization, the most common co-covered peer. We currently track 1 Biotech story that mention Dilation and Curettage (D&C), all published on July 21, 2026. Each carries 2 original sources on average.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 10 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Dilation and Curettage (D&C). Shared-story counts are live from our verified record — not editorial picks.
Regulatory chaos after Dobbs is freezing innovation in miscarriage management drugs and devices, delaying emergency care and leaving a $2.3 billion women’s health market in limbo. Vague exceptions in 13 state bans create a minefield for pharma companies developing early pregnancy loss treatments.
Source: reporterherald.com · sun-sentinel.com
Dilation and Curettage (D&C) is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
